(Reuters) -AstraZeneca said on Monday it would pay up to $1.92 billion to CSPC Pharmaceutical Group Ltd in an exclusive licence agreement to boost the Anglo-Swedish drugmaker's cardiovascular pipeline ...

On Monday, AstraZeneca plc (NASDAQ:AZN) entered into an exclusive license agreement with Hong Kong-based CSPC Pharmaceutical Group Ltd to advance the development of an early-stage, novel ...

(Reuters) -AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for ...

AstraZeneca has licensed a small-molecule lipoprotein disruptor from China’s CSPC Pharmaceutical Group for $100 million. The molecule is intended to prevent formation of lipoprotein(a), high ...

AstraZeneca PLC (NASDAQ:AZN) is one of the 11 Best Strong Buy Stocks to Invest in Now. On June 13, AstraZeneca PLC (NASDAQ:AZN) announced that it had entered into a strategic research collaboration ...

AstraZeneca (NASDAQ:AZN) is looking to boost its cardiovascular pipeline through an exclusive license agreement with CSPC Pharmaceutical Group (CSPC). As part of the deal, AstraZeneca will pay $100M ...

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Friday that it has entered into a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Lts, ...

To soften the blow, CSPC has accelerated its shift from generic drugs to innovative medicines. In the first three quarters, the company's spending on R&D rose 7.9% to 4.19 billion yuan, equivalent to ...

Astrazeneca plc is adding a preclinical-stage candidate to its cardiovascular pipeline via a potentially $2 billion licensing agreement with CSPC Pharmaceutical Group Ltd., which includes a $100 ...

AstraZeneca PLC (NASDAQ:AZN) is one of the 11 Best Strong Buy Stocks to Invest in Now. On June 13, AstraZeneca PLC (NASDAQ:AZN) announced that it had entered into a strategic research collaboration ...